B
Bayland Capital
Beijing
Overview
Bayland Capital is a venture capital firm founded in 2019 with a background from the biopharmaceutical company Pharmaron. The firm specializes in equity investments within the biomedical sector, focusing on innovative life science companies, drug R&D platforms, novel therapeutics, and medical device companies globally.
Year Founded
2019
Portfolio Companies
4
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Cascade Pharmaceuticals, Inc. | Feb 2026 | Series C | Co-investor |
| BridGene Biosciences | Oct 2025 | Series B Extension | Lead |
| Shanghai LePure Biotechnology Co., Ltd. | Jan 2023 | Series C | Co-investor |
| TrueLab Biopharmaceutical | - | VC Round | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
